About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
F
Altering the Mitochondrial Potential as a Therapeutic Approach in B-cell Lymphoma
By
Francisco Hernandez-Ilizaliturri
105 views
May 7, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
13:16
ASH 2022 Conference Coverage
Experts Discuss Key Updates in CLL
Feat.
S. O'Brien,
C. Coombs
27:14
2024 Clinical Case Studies
Clinical Case Review: Cutaneous T Cell Lymphoma in the Patch Test Cl…
Feat.
J. Murase
10:35
Alan Skarbnik
Learnings From the ELEVATE-TN Phase 3 Trial: Acalabrutinib+/-Obinutu…
04:14
ecancer
ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for…
Feat.
J. Brown
18:04
Seema Bhat
Zanubrutinib for the Treatment of CLL: Learnings From ALPINE, SEQUOI…
06:53
Fred Hutchinson Cancer Center
Surveying Safety and Efficacy Data in R/R CLL: ALPINE and ELEVATE-RR…
Feat.
M. Shadman
13:27
Benjamin Heyman
Recent Updates in CLL
16:43
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
Advances in CLL and Mantle Cell Lymphoma
Feat.
E. Chong
17:23
Current Challenges in Hematology
2023 Updates on Sequencing in CLL
Feat.
L. Scarfò
09:33
Adam Kittai
Chemo-Free Approaches in the Frontline Setting of CLL: Treatment Goa…
12:06
Catherine Coombs
New BTKi in CLL
24:11
Jennifer Brown
State of the Art & Next Questions: CLL
14:21
Masterclasses in Dermatology
Comorbidities of Psoriasis and PsA
Feat.
J. Cohen
09:33
City of Hope
Assessing Comorbidities in CLL
Feat.
A. Danilov
09:35
UNC Lineberger Comprehensive Cancer Center
The Importance of Molecular Testing for Therapeutic Decision Making …
Feat.
C. Coombs
09:12
Julia Erin Wiedmeier-Nutor
Del(17p) and TP53 Mutations in CLL and MM: Overview and Treatment Re…
43:53
PleXus Communications
Clinical Practices for Optimizing the Use of BTK Inhibitors for the …
Feat.
M. Davids
67:23
University of Louisville
CAR T-Cell Therapy has Redefined the Treatment Algorithm for Relapse…
Feat.
M. Kharfan-Dabaja
08:19
RWCS
RWCS 2021 Highlights on Biologics/tsDMARDs: What Are the Commonly Co…
Feat.
A. Kavanaugh,
J. Cush
07:00
8th Eurasian Hematology Oncology Summit
MRD in CLL: What Were the Changes and Issues Over the Years? Is This…
Feat.
R. Foa
